[5] Early adjuvant therapy -- replacing tamoxifen therapy with aromatase inhibitor therapy during the first 5 years after surgery; Early sequential adjuvant therapy -- sequencing of tamoxifen and ...

Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor ...

ARIANNA 1 is a non-steroidal aromatase inhibitor, which reduces the amount of estrogen (female sex hormone) made by the body. In some types of breast cancer, estrogen can help the cancer cells grow.

Opens in a new tab or window For children with nephrotic syndrome, there was no difference in time to relapse between two commonly used non-steroid ... a calcineurin inhibitor compared with ...

Fifty five out of 151 consecutive admissions to a dysphagia clinic were found to have benign oesophageal stricture. Twenty six out of 53 (49%) had been prescribed non-steroidal anti-inflammatory drugs ...

a non-steroidal aromatase inhibitor. Forward-Looking Statements This press release contains “forward-looking statements” that involve substantial risks and uncertainties. All statements other ...

Among these, cyclooxygenase (COX) inhibitors, particularly selective ... side effects commonly associated with traditional non-steroidal anti-inflammatory drugs (NSAIDs). Recent research has ...

A Chinese study, led by Arnold ASH Chee, AFCOphthHK, found that a tyrosine kinase inhibitor achieved both durable disease control and visual improvement in patients with epidermal growth factor ...